New Jersey Innovation Institute (NJII) announced the sale of its subsidiary, BioCentriq Inc., to GC corp. for $73 million. BioCentriq manufactures autologous and allogeneic cell therapies and gene therapies and specializes in viral vector production, cell and viral banking, and upstream and downstream processing.Read more
CaroGen Partners with BioCentriq™ for Clinical Production of its Virus-like Vesicle (VLV) Immunotherapy for Chronic Hepatitis B Viral Infection (CHB)
CaroGen Corporation partners with BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trial. Learn more.Read more
FOR IMMEDIATE RELEASE: Virtual ribbon cutting and tour featured remarks from New Jersey Governor Phil Murphy, FDA’s Peter Marks, as well as panel discussions with industry leaders from ARM, NIIMBL, Century Therapeutics, BioNJ, NJEDA, NJIT …Read more
The New Jersey Innovation Institute (NJII) and Choose New Jersey will be hosting a virtual ribbon cutting, tour and panel discussions to mark the opening of BioCentriq™ on Thursday, October 29 at 2:30pm. RSVP to …Read more
BioCentriq Name of First Cell and Gene Therapy Development and Manufacturing Center Located on a University Campus in the U.S.
NJII announces that qualification and validation of its clinical manufacturing facility for cell and gene therapies is underway, and the name of the center will be BioCentriq. May 4, 2020: Newark, N.J. – Today the …Read more